Aflibercept in the real world–an EPR based clinical audit of patients with diabetic macular edema from 21 UK hospitals

Mahmood, Sajjad, Stratton, Irene, Mukherjee, Rajarshi, Talks, James S., Bailey, Clare, Lotery, Andrew, Kashani, Shahram, Ghanchi, Faruque, Natha, Salim and Scanlon, Peter Henry (2019) Aflibercept in the real world–an EPR based clinical audit of patients with diabetic macular edema from 21 UK hospitals. Investigative Ophthalmology & Visual Science, 60 (9), 2626.

Abstract

Purpose: Aflibercept was licenced in UK for use as treatment for diabetic macular edema in 2015. Here we report on real life experience in 21 UK hospitals. Methods: Anonymised data of patients undergoing anti-VEGF injections for diabetic macular edema was exported from a dedicated ophthalmology electronic patient record system. Those who had aflibercept injections only were included. For those who had both eyes treated, only the first eye to be treated was included and for those who had both eyes treatment started simultaneously, the better eye was included. Linear regression was used to relate change in visual acuity (VA) over 12 months from the first injection with age (grouped< 65 years, 65 to 74, 75 and above), baseline letter score (< 50 letters, 50 to 59, 60 to 69, 70 to 79, 80 or more) and number of injections.

This record has no associated files available for download.

Contributors

Author: Andrew Lotery

Download statistics